JP2024519487A5 - - Google Patents
Info
- Publication number
- JP2024519487A5 JP2024519487A5 JP2023567930A JP2023567930A JP2024519487A5 JP 2024519487 A5 JP2024519487 A5 JP 2024519487A5 JP 2023567930 A JP2023567930 A JP 2023567930A JP 2023567930 A JP2023567930 A JP 2023567930A JP 2024519487 A5 JP2024519487 A5 JP 2024519487A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- carboxamide
- oxopiperazine
- chloro
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185608P | 2021-05-07 | 2021-05-07 | |
| US63/185,608 | 2021-05-07 | ||
| PCT/US2022/027262 WO2022235558A1 (en) | 2021-05-07 | 2022-05-02 | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024519487A JP2024519487A (ja) | 2024-05-14 |
| JP2024519487A5 true JP2024519487A5 (enExample) | 2024-06-05 |
| JP7846132B2 JP7846132B2 (ja) | 2026-04-14 |
Family
ID=83932809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567930A Active JP7846132B2 (ja) | 2021-05-07 | 2022-05-02 | Ｎａｖ１．８阻害薬としてのアリール ３－オキソピペラジンカルボキサミド類及びヘテロアリール ３－オキソピペラジンカルボキサミド類 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240246932A1 (enExample) |
| EP (1) | EP4334306A4 (enExample) |
| JP (1) | JP7846132B2 (enExample) |
| KR (1) | KR20240006606A (enExample) |
| CN (1) | CN117597339A (enExample) |
| AU (1) | AU2022270061B2 (enExample) |
| BR (1) | BR112023023186A2 (enExample) |
| CA (1) | CA3217605A1 (enExample) |
| MX (1) | MX2023013147A (enExample) |
| WO (1) | WO2022235558A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0515133A (pt) * | 2004-08-30 | 2008-07-08 | Neuromed Pharmaceuticals Ltd | derivados de uréia como bloqueadores do canal de cálcio |
| US7767680B2 (en) * | 2004-11-03 | 2010-08-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| EP1995241B1 (en) * | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
| WO2011026240A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| JP7288051B2 (ja) * | 2018-11-02 | 2023-06-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類 |
| CN115697327A (zh) | 2020-06-17 | 2023-02-03 | 默沙东有限责任公司 | 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺 |
| US12516046B2 (en) | 2020-06-17 | 2026-01-06 | Merck Sharp & Dohme Llc | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| GEP20257795B (en) | 2021-05-07 | 2025-09-25 | Merck Sharp & Dohme Llc | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
-
2022
- 2022-05-02 AU AU2022270061A patent/AU2022270061B2/en active Active
- 2022-05-02 US US18/557,667 patent/US20240246932A1/en active Pending
- 2022-05-02 EP EP22799359.9A patent/EP4334306A4/en active Pending
- 2022-05-02 BR BR112023023186A patent/BR112023023186A2/pt unknown
- 2022-05-02 JP JP2023567930A patent/JP7846132B2/ja active Active
- 2022-05-02 MX MX2023013147A patent/MX2023013147A/es unknown
- 2022-05-02 KR KR1020237042102A patent/KR20240006606A/ko active Pending
- 2022-05-02 CN CN202280047884.9A patent/CN117597339A/zh active Pending
- 2022-05-02 WO PCT/US2022/027262 patent/WO2022235558A1/en not_active Ceased
- 2022-05-02 CA CA3217605A patent/CA3217605A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519487A5 (enExample) | ||
| JP2023530319A5 (enExample) | ||
| JP2023530320A5 (enExample) | ||
| IL299180A (en) | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | |
| JP2019533694A5 (enExample) | ||
| JP2021504443A5 (enExample) | ||
| JP2013501749A5 (enExample) | ||
| RU2015150946A (ru) | Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2020536116A5 (enExample) | ||
| JP2023506642A5 (enExample) | ||
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| JP2016523911A5 (enExample) | ||
| CA2418868A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| JP2009529047A5 (enExample) | ||
| JP2020511452A5 (enExample) | ||
| RU2010125220A (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| JP2021535134A5 (enExample) | ||
| RU2005131165A (ru) | Производные имидазол-4-илэтинилпиридина | |
| JP2016523976A5 (enExample) | ||
| RU2014107463A (ru) | Селективные ингибиторы протеинкиназ | |
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
| JP2020503293A5 (enExample) | ||
| JP2018521119A5 (enExample) |